NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$5.4b

Last Updated

2021/04/15 22:57 UTC

Data Sources

Company Financials +

Executive Summary

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. More Details


Snowflake Analysis

Reasonable growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has NeoGenomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: NEO's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

3.5%

NEO

3.4%

US Life Sciences

1.6%

US Market


1 Year Return

75.8%

NEO

66.4%

US Life Sciences

57.5%

US Market

Return vs Industry: NEO exceeded the US Life Sciences industry which returned 66.4% over the past year.

Return vs Market: NEO exceeded the US Market which returned 57.5% over the past year.


Shareholder returns

NEOIndustryMarket
7 Day3.5%3.4%1.6%
30 Day-1.3%8.4%3.4%
90 Day-6.1%3.2%8.6%
1 Year75.8%75.8%66.7%66.4%60.3%57.5%
3 Year437.3%437.3%115.9%114.7%62.6%51.9%
5 Year605.7%605.7%216.2%212.5%119.9%95.3%

Long-Term Price Volatility Vs. Market

How volatile is NeoGenomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NeoGenomics undervalued compared to its fair value and its price relative to the market?

1289.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: NEO ($49.54) is trading above our estimate of fair value ($27.65)

Significantly Below Fair Value: NEO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NEO is poor value based on its PE Ratio (1289.3x) compared to the US Life Sciences industry average (46.4x).

PE vs Market: NEO is poor value based on its PE Ratio (1289.3x) compared to the US market (22.3x).


Price to Earnings Growth Ratio

PEG Ratio: NEO is poor value based on its PEG Ratio (16.6x)


Price to Book Ratio

PB vs Industry: NEO's PB Ratio (8x) is in line with the US Life Sciences industry average.


Future Growth

How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

77.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEO's forecast earnings growth (77.5% per year) is above the savings rate (2%).

Earnings vs Market: NEO's earnings (77.5% per year) are forecast to grow faster than the US market (18.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NEO's revenue (12.3% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: NEO's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NEO's Return on Equity is forecast to be low in 3 years time (6%).


Past Performance

How has NeoGenomics performed over the past 5 years?

45.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEO has a large one-off gain of $4.9M impacting its December 31 2020 financial results.

Growing Profit Margin: NEO's current net profit margins (0.9%) are lower than last year (1.9%).


Past Earnings Growth Analysis

Earnings Trend: NEO has become profitable over the past 5 years, growing earnings by 45.9% per year.

Accelerating Growth: NEO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: NEO had negative earnings growth (-47.6%) over the past year, making it difficult to compare to the Life Sciences industry average (7.4%).


Return on Equity

High ROE: NEO's Return on Equity (0.6%) is considered low.


Financial Health

How is NeoGenomics's financial position?


Financial Position Analysis

Short Term Liabilities: NEO's short term assets ($448.7M) exceed its short term liabilities ($73.2M).

Long Term Liabilities: NEO's short term assets ($448.7M) exceed its long term liabilities ($220.9M).


Debt to Equity History and Analysis

Debt Level: NEO's debt to equity ratio (24.8%) is considered satisfactory.

Reducing Debt: NEO's debt to equity ratio has reduced from 25.9% to 24.8% over the past 5 years.

Debt Coverage: NEO's debt is not well covered by operating cash flow (0.8%).

Interest Coverage: Insufficient data to determine if NEO's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is NeoGenomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Doug VanOort (65 yo)

11.5yrs

Tenure

US$3,648,732

Compensation

Mr. Douglas M. VanOort, also known as Doug, has been the Chairman and Chief Executive Officer of NeoGenomics Inc. since October 28, 2009. Mr. VanOort has been the Executive Chairman and Chief Executive Off...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD3.65M) is below average for companies of similar size in the US market ($USD6.51M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NEO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: NEO's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.


Top Shareholders

Company Information

NeoGenomics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NeoGenomics, Inc.
  • Ticker: NEO
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.379b
  • Shares outstanding: 116.94m
  • Website: https://www.neogenomics.com

Number of Employees


Location

  • NeoGenomics, Inc.
  • 12701 Commonwealth Drive
  • Suite 9
  • Fort Myers
  • Florida
  • 33913
  • United States

Listings


Biography

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers te...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/15 22:57
End of Day Share Price2021/04/15 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.